Elan Corp PLC (ELN.I)
4.55EUR
4:03am EST
€0.03 (+0.66%)
€4.52
€4.55
€4.56
€4.55
9,360
397,181
€7.00
€3.15
About
Overall
| Beta: | 0.86 |
| Market Cap (Mil.): | €2,647.85 |
| Shares Outstanding (Mil.): | 583.74 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| ELN.I | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 3.56 | 4.64 |
| EPS (TTM): | 92.57 | -- | -- |
| ROI: | -3.03 | 1.78 | 2.79 |
| ROE: | -- | 2.39 | 3.51 |
UPDATE 1-J&J to pay $785 million for sinus-surgery company
* Cash deal includes other ear, nose, throat technology
UPDATE 4-Elan, Transition drop top drug doses after deaths
* Nine deaths in patients on top doses of Alzheimer's drug
WRAPUP 1-Addex drug flop deals blow to European biotech
* Elan, Transition hit by Alzheimer's drug setback (Adds analyst and company comment, industry detail)
RPT-UPDATE 2-Elan, Transition drop top drug doses after deaths
* Nine deaths in patients on top doses of Alzheimer's drug
UPDATE 2-HealthCor slams Biogen CEO for outsize pay package
* Calls on company to initiate sustained buyback program
Elan, Biogen change Tysabri label due to PML risk
DUBLIN, Nov 7 (Reuters) - Ireland's Elan and U.S. drugmaker Biogen Idec have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on Saturday.
J&J slashing workforce
NEW YORK (Reuters) - Johnson & Johnson plans to cut up to 7 percent of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to weather future challenges, the diversified healthcare company said on Tuesday.
J&J to slash 7,000 to 8,000 jobs
NEW YORK (Reuters) - Johnson & Johnson plans to cut up to 7 percent of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to weather future challenges, the diversified healthcare company said on Tuesday.
UPDATE 4-J&J slashing workforce, cites cost of drug research
* Shares down 0.7 pct (Adds details on earlier job cuts, recent drug deals)
Europe stocks post first monthly drop since June
LONDON, Oct 30 (Reuters) - European shares fell sharply on Friday on mixed U.S. data and as traders booked profits while a key index reversed its monthly rising trend for the first time since June.





Earnings vs
Estimates